NO763196L - PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES. - Google Patents
PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES.Info
- Publication number
- NO763196L NO763196L NO763196A NO763196A NO763196L NO 763196 L NO763196 L NO 763196L NO 763196 A NO763196 A NO 763196A NO 763196 A NO763196 A NO 763196A NO 763196 L NO763196 L NO 763196L
- Authority
- NO
- Norway
- Prior art keywords
- benzimidazole
- carbomethoxyamino
- phenylsulfonyloxy
- acid chloride
- benzenesulfonic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 4
- -1 benzenesulfonic acid halide Chemical class 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ONCAZCNPWWQQMW-UHFFFAOYSA-N 3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC(S(Cl)(=O)=O)=C1 ONCAZCNPWWQQMW-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N 3-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(Br)=C1 PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 2
- OINWZUJVEXUHCC-UHFFFAOYSA-N 3-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(S(Cl)(=O)=O)=C1 OINWZUJVEXUHCC-UHFFFAOYSA-N 0.000 description 2
- JHJKSEKUZNJKGO-UHFFFAOYSA-N 3-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC(S(Cl)(=O)=O)=C1 JHJKSEKUZNJKGO-UHFFFAOYSA-N 0.000 description 2
- KFPMLWUKHQMEBU-UHFFFAOYSA-N 3-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC(S(Cl)(=O)=O)=C1 KFPMLWUKHQMEBU-UHFFFAOYSA-N 0.000 description 2
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VIODWHADHIMZJO-UHFFFAOYSA-N (4-amino-3-nitrophenyl) benzoate Chemical compound C1=C([N+]([O-])=O)C(N)=CC=C1OC(=O)C1=CC=CC=C1 VIODWHADHIMZJO-UHFFFAOYSA-N 0.000 description 1
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FREOGXBZEAMJQN-UHFFFAOYSA-N 2,4-dimethylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C(C)=C1 FREOGXBZEAMJQN-UHFFFAOYSA-N 0.000 description 1
- BXCOSWRSIISQSL-UHFFFAOYSA-N 2,5-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(Cl)C(S(Cl)(=O)=O)=C1 BXCOSWRSIISQSL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VFPWGZNNRSQPBT-UHFFFAOYSA-N 2-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1Br VFPWGZNNRSQPBT-UHFFFAOYSA-N 0.000 description 1
- QFNSAOSWJSCHID-UHFFFAOYSA-N 2-butylbenzenesulfonic acid Chemical compound CCCCC1=CC=CC=C1S(O)(=O)=O QFNSAOSWJSCHID-UHFFFAOYSA-N 0.000 description 1
- JWFLSLOCDIEDGQ-UHFFFAOYSA-N 2-chloro-4-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 JWFLSLOCDIEDGQ-UHFFFAOYSA-N 0.000 description 1
- FJVZVTWCAGCLCS-UHFFFAOYSA-N 2-chloro-6-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC(Cl)=C1S(Cl)(=O)=O FJVZVTWCAGCLCS-UHFFFAOYSA-N 0.000 description 1
- KMVZDSQHLDGKGV-UHFFFAOYSA-N 2-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC=C1S(Cl)(=O)=O KMVZDSQHLDGKGV-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- NYIBPWGZGSXURD-UHFFFAOYSA-N 3,4-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1Cl NYIBPWGZGSXURD-UHFFFAOYSA-N 0.000 description 1
- RJSQINMKOSOUGT-UHFFFAOYSA-N 3,5-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC(Cl)=CC(S(Cl)(=O)=O)=C1 RJSQINMKOSOUGT-UHFFFAOYSA-N 0.000 description 1
- GNYVVCRRZRVBDD-UHFFFAOYSA-N 3-chloro-4-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1Cl GNYVVCRRZRVBDD-UHFFFAOYSA-N 0.000 description 1
- NHXWTFAPVNWYJI-UHFFFAOYSA-N 4-(2-methylpropoxy)benzenesulfonyl chloride Chemical compound CC(C)COC1=CC=C(S(Cl)(=O)=O)C=C1 NHXWTFAPVNWYJI-UHFFFAOYSA-N 0.000 description 1
- IQXUIDYRTHQTET-UHFFFAOYSA-N 4-amino-3-nitrophenol Chemical compound NC1=CC=C(O)C=C1[N+]([O-])=O IQXUIDYRTHQTET-UHFFFAOYSA-N 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- HGKWMUBXVMFXNC-UHFFFAOYSA-N 4-butoxybenzenesulfonyl chloride Chemical compound CCCCOC1=CC=C(S(Cl)(=O)=O)C=C1 HGKWMUBXVMFXNC-UHFFFAOYSA-N 0.000 description 1
- DTMRZJATPXTPSM-UHFFFAOYSA-N 4-chloro-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC(Cl)=CC=C1S(Cl)(=O)=O DTMRZJATPXTPSM-UHFFFAOYSA-N 0.000 description 1
- WEPYREBDJIVOHD-UHFFFAOYSA-N 4-chloro-3-methylbenzenesulfonyl chloride Chemical compound CC1=CC(S(Cl)(=O)=O)=CC=C1Cl WEPYREBDJIVOHD-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- IJWCRHKAQNFJLT-UHFFFAOYSA-N 4-propan-2-yloxybenzenesulfonyl chloride Chemical compound CC(C)OC1=CC=C(S(Cl)(=O)=O)C=C1 IJWCRHKAQNFJLT-UHFFFAOYSA-N 0.000 description 1
- LHYZGURMLPSRFU-UHFFFAOYSA-N 4-propoxybenzenesulfonyl chloride Chemical compound CCCOC1=CC=C(S(Cl)(=O)=O)C=C1 LHYZGURMLPSRFU-UHFFFAOYSA-N 0.000 description 1
- VHBFBNCERXCECQ-UHFFFAOYSA-N 5-chloro-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(Cl)C=C1S(Cl)(=O)=O VHBFBNCERXCECQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CVHQHBTZJJLPAB-UHFFFAOYSA-M C[S+]=C(N)N.[O-]S(O)(=O)=O Chemical compound C[S+]=C(N)N.[O-]S(O)(=O)=O CVHQHBTZJJLPAB-UHFFFAOYSA-M 0.000 description 1
- 241000893172 Chabertia Species 0.000 description 1
- 241001126268 Cooperia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000243976 Haemonchus Species 0.000 description 1
- 241000243974 Haemonchus contortus Species 0.000 description 1
- 241000920462 Heterakis Species 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241001547406 Hyostrongylus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000510960 Oesophagostomum Species 0.000 description 1
- 241000243795 Ostertagia Species 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000244174 Strongyloides Species 0.000 description 1
- 241000243797 Trichostrongylus Species 0.000 description 1
- 241000243796 Trichostrongylus colubriformis Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical group 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
Fremgangsmåte til fremstilling av antelmintisk virksomme 2-karbalkoksyamino-5-(6) - f enyl-sulf onyloksy-benzimidazoler. Process for the production of anthelminthically active 2-carbalkoxyamino-5-(6)-phenyl-sulfonyloxy-benzimidazoles.
2-karbaloksy-amino-benzimidazolylderivater med alkyl, acyl-, fenoksy- og fenyltioester i 5(6)-stilling er kjent som antelmintica (P. Actor et al., Nature 215, 321 (1967), DOS 2.029.637, DOS 2.164.690, DOS 2.363.348). 2-Carbaloxy-amino-benzimidazolyl derivatives with alkyl, acyl, phenoxy and phenylthioesters in the 5(6) position are known as antelmintica (P. Actor et al., Nature 215, 321 (1967), DOS 2,029,637, DOS 2,164,690, DOS 2,363,348).
Oppfinnelsens gjenstand er en fremgangsmåte til fremstilling av antelmintisk virksomme 2-karbalkoksyamino-5(6)-fenyl-sulfonyloksy-benzimidazol med formel (1) The object of the invention is a method for the production of anthelminthically active 2-carbaloxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole with formula (1)
hvori R betyr alkyl med 1 til 4 C-atomer, R2og R betyr hver uavhengig av hverandre hydrogen, hydroksyl, alkoksy med 1 til 4 C-atomer, halogen, trifluormetyl, alkyl med 1 til 4 C-atomer, karbalkoksy med 1 til 4 C-atomer i alkoksyresten eller CN, idet fremgangsmåten erkarakterisert vedat et 2-karbalkoksyamin-5(6)-hydroksy-benzimidazol med formel (2), hvori har samme betydning som ovenfor omsettes i nærvær av en base med et benzensulfonsyrehalogenid med formel (3) wherein R means alkyl with 1 to 4 C atoms, R 2 and R each independently means hydrogen, hydroxyl, alkoxy with 1 to 4 C atoms, halogen, trifluoromethyl, alkyl with 1 to 4 C atoms, carboxyl with 1 to 4 C atoms in the alkoxy radical or CN, the method being characterized by a 2-carbaloxyamine-5(6)-hydroxy-benzimidazole of formula (2), in which has the same meaning as above, is reacted in the presence of a base with a benzenesulfonic acid halide of formula (3 )
hvori R2og R3har samme betydning som ovenfor og X betyr fluor, klor eller brom. For omsetningen er det foretrukket benzensulfonsyreklorid med formel (3). in which R2 and R3 have the same meaning as above and X means fluorine, chlorine or bromine. For the reaction, benzenesulfonic acid chloride with formula (3) is preferred.
Som alkylrester for substituentene R^, og R^kommer det i betraktning: metyl, etyl, propyl, isopropyl, butyl, sekundær-butyl, tertiær-butyl. Som alkoksygrupper for substituentene R^og R^kommer det i betraktning: metoksy, etoksy, propoksy, isopropoksy og butoksy. Som halogenatom for substituentene R2og R^kommer det i betraktning: fluor, klor, brom og jod. Som karbalkoksygrupper for substituentene R2og R^kommer det i betraktning:, karbometoksy, karbetoksy, karbopropoksy eller karbobu-toksy. As alkyl residues for the substituents R^, and R^ the following come into consideration: methyl, ethyl, propyl, isopropyl, butyl, secondary-butyl, tertiary-butyl. The following methoxy, ethoxy, propoxy, isopropoxy and butoxy are considered as alkoxy groups for the substituents R^ and R^. As a halogen atom for the substituents R 2 and R 2 the following are considered: fluorine, chlorine, bromine and iodine. Carbomethoxy groups for the substituents R 2 and R 4 come into consideration: carbomethoxy, carbethoxy, carbopropoxy or carbobutoxy.
Spesielt foretrukket er forbindelser med formel (1), hvori R^betyr metyl, etyl, propyl eller butyl, R2betyr hydrogen eller klor og R^betyr hydrogen, klor eller trifluormetyl. Particularly preferred are compounds of formula (1), in which R₂ means methyl, ethyl, propyl or butyl, R₂ means hydrogen or chlorine and R₂ means hydrogen, chlorine or trifluoromethyl.
Reaksjonsforløpet kan gjengis med følgende skjema The course of the reaction can be reproduced with the following form
For gjennomføring av reaksjonen suspenderer man et 2-karbalkoksy-amino-5(6)-hydroksy-benzimidazol med formel (2) i et aprotisk oppløsningsmiddel med et tertiært amin og tildrypper under omrøring en oppløsning av benzylensulfonsyrehalogenider med formel (3). Blandingen omrøres inntil omsetningen er avsluttet, idet man bestemmer tidspunktet hensiktsmessig ved hjelp av en To carry out the reaction, a 2-carbalkoxy-amino-5(6)-hydroxy-benzimidazole of formula (2) is suspended in an aprotic solvent with a tertiary amine and a solution of benzylene sulfonic acid halides of formula (3) is added dropwise while stirring. The mixture is stirred until the turnover is finished, the time being determined appropriately with the help of a
tynn sjiktokromatisk kontroll.thin layer chromatic control.
Som 2-karbalkoksyamino-5(6)-hydroksy-benzimidazol med formel (2) kommer det eksempelvis på tale As 2-carbalkoxyamino-5(6)-hydroxy-benzimidazole with formula (2) it is mentioned, for example
2-karbometoksyamino-2(6)-hydroksy-benzimidazol 2-karboetoksya-ino-5(6)-hydroksy-benzimidazol 2-carbomethoxyamino-2(6)-hydroxy-benzimidazole 2-carboethoxy-ino-5(6)-hydroxy-benzimidazole
2-karbisopropoksyamino-5(6)-hydroksy-benzimidazol 2-karbobutoksyamino-5(6)-hydroksy-benzimidazol 2-karbisobutoksyamino-5(6)-hydroksy-benzimidazol 2- karbotert.butoksyamino-5(6)-hydroksy-benzimidazol 2-carbisopropoxyamino-5(6)-hydroxy-benzimidazole 2-carbobutoxyamino-5(6)-hydroxy-benzimidazole 2-carbisobutoxyamino-5(6)-hydroxy-benzimidazole 2- carbotert.butoxyamino-5(6)-hydroxy-benzimidazole
Som aprotisk oppløsningsmiddel skal det nevnes aceton, tetrahydrofuran, dioksan, dietyleter, diisopropyleter, dimetylformamid, dimetylsulfoksyd, tetrametylurinstoff og liknende dipolare, aprotiske oppløsningsmidler. Acetone, tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, dimethylformamide, dimethylsulfoxide, tetramethylurea and similar dipolar, aprotic solvents should be mentioned as aprotic solvents.
Som baser kommer det på tale alkali- eller jordalkali-hydroksyder, -karbonater og -hydrogenkarbonater eller tertiære organiske baser. Som eksempler skal nevnes: natriumhydroksyd, natriumhydrogenkarbonat, natriumkarbonat, kaliumkarbonat, kalium-hydrogenkarbonat, trietylamin, pyridin og metyl-substituerte pyridiner. Bases include alkali or alkaline earth hydroxides, carbonates and hydrogen carbonates or tertiary organic bases. Examples include: sodium hydroxide, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium hydrogen carbonate, triethylamine, pyridine and methyl-substituted pyridines.
Som benzensulfonsyrehalogenider med formel (3) kommer eksempelvis i betraktning: As benzenesulfonic acid halides with formula (3) come into consideration, for example:
benzensulfonsyre-kloridbenzenesulfonic acid chloride
4-klor-benzensulfonsyre-klorid4-chloro-benzenesulfonic acid chloride
3- klor-benzensulfonsyre-klorid3-chloro-benzenesulfonic acid chloride
2- klor-benzensulfonsyre-klorid 2-chloro-benzenesulfonic acid chloride
2,5-diklor-benzensulfonsyre-klorid 2,5-dichlorobenzenesulfonic acid chloride
3.4- diklor-benzensulfonsyre-klorid 3.4-Dichlorobenzenesulfonic acid chloride
3.5- diklor-benzensulfonsyre-klorid 3.5-Dichlorobenzenesulfonic acid chloride
4- brom-benzensulfonsyre-klorid4-bromo-benzenesulfonic acid chloride
3- brom-benzensulfonsyre-klorid3-bromo-benzenesulfonic acid chloride
2- brom-benzensulfonsyre-klorid 2-bromo-benzenesulfonic acid chloride
4- metyl-benzensulfonsyre-klorid 4- Methyl-benzenesulfonic acid chloride
3- metyl-benzensulfonsyre-klorid 3- methyl-benzenesulfonic acid chloride
2-metyl-benzensulfonsyre-klorid 2-methyl-benzenesulfonic acid chloride
4- tert.butyl-benzensulfonsyre-klorid 4-tert.butyl-benzenesulfonic acid chloride
2,4-dimetyl-benzensulfonsyre-klorid 2,4-dimethylbenzenesulfonic acid chloride
2-klor-4-metyl-benzensulfonsyre-klorid 2-chloro-4-methyl-benzenesulfonic acid chloride
2-klor-6-metyl-benzensulfonsyre-klorid 2-chloro-6-methyl-benzenesulfonic acid chloride
3-klor-4-metyl-benzensulfonsyre-klorid 3-chloro-4-methyl-benzenesulfonic acid chloride
3- klor-6-metyl-benzensulfonsyre-klorid 3-chloro-6-methyl-benzenesulfonic acid chloride
4- klor-2-metyl-benzensulfonsyre-klorid 4-chloro-2-methyl-benzenesulfonic acid chloride
4-klor-3-metyl-benzensulfonsyre-klorid 4-chloro-3-methyl-benzenesulfonic acid chloride
4-klor-3,5-dimetyl-benzensulfonsyre-klorid 4-chloro-3,5-dimethyl-benzenesulfonic acid chloride
3- trifluormetyl-benzensulfonsyre-klorid 3-trifluoromethyl-benzenesulfonic acid chloride
4- metoksy-benzensulfonsyre-klorid4- methoxy-benzenesulfonic acid chloride
3-metoksy-benzensulfonsyre-klorid3-Methoxy-benzenesulfonic acid chloride
3- metoksy-benzensulfonsyre-klorid 3-Methoxy-benzenesulfonic acid chloride
4- propoksy-benzensulfonsyre-klorid 4- propoxy-benzenesulfonic acid chloride
4-isopropoksy-benzensulfonsyre-klorid 4-isopropoxy-benzenesulfonic acid chloride
4-butoksy-benzensulfonsyre-klorid 4-butoxy-benzenesulfonic acid chloride
4-isobutoksy-benzensulfonsyre-klorid4-isobutoxy-benzenesulfonic acid chloride
Reaksjonstemperaturområdet ligger mellom 0 og 60°C/fortrinnsvis mellom 15 og 30°C. Omsetningens hastighet avhenger av det anvendte benzensulfonsyreklorids reaksjonsevne således at varigheten kan variere fra få timer inntil en dag. The reaction temperature range is between 0 and 60°C/preferably between 15 and 30°C. The speed of the reaction depends on the reactivity of the benzene sulphonic acid chloride used, so that the duration can vary from a few hours to a day.
Reaksjonens fremmadskridning lar seg følge ved tynnsjikt-kromatografisk kontroll, idet man hensiktsmessig som adsorbens anvender kieselgel og som løpemiddel blandinger av kloroform, eddiksyreetylester og iseddik, fortrinnsvis i forhold-et 10:10:1. The progress of the reaction can be monitored by thin-layer chromatographic control, using silica gel as an adsorbent and mixtures of chloroform, ethyl acetate and glacial acetic acid as eluent, preferably in a ratio of 10:10:1.
Reaksjonsproduktene isoleres ved filtrering fra reaksjonsblandingen. Man får således: 2-karbometoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-karbometoksyamino-5(6)-(4-klor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(3-klor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(2-klor-fenylsulfonyloksy)-benzimidazol The reaction products are isolated by filtration from the reaction mixture. One thus obtains: 2-carbomethoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2-carbomethoxyamino-5(6)-(4-chloro-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(3-chloro-phenylsulfonyloxy) -benzimidazole 2-carbomethoxyamino-5(6)-(2-chloro-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(2,5-diklor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(3,4-diklor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(3,5-diklor-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(4-brom-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(2,5-dichloro-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(3,4-dichloro-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-( 3,5-dichloro-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(4-bromo-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(3-brom-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(2-brom-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(4-metyl-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(3-metyl-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(2-metyl-fenylsulfonyloksy)-benzimidazol 2-karbometoksyamino-5(6)-(4-tert.butyl-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(3-bromo-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(2-bromo-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(4-methyl- phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(3-methyl-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-(2-methyl-phenylsulfonyloxy)-benzimidazole 2-carbomethoxyamino-5(6)-( 4-tert.butyl-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(2-klor-4-metyl-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(2-chloro-4-methyl-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(2-klor-6-metyl-fenylsulfonyloksy)benzimidazol 2-carbomethoxyamino-5(6)-(2-chloro-6-methyl-phenylsulfonyloxy)benzimidazole
2-karbometoksyamino-5(6)-(3-klor-4-metyl-fenylsulfonyloksy)-benz-imidazol 2-carbomethoxyamino-5(6)-(3-chloro-4-methyl-phenylsulfonyloxy)-benz-imidazole
2-karbometoksyamino-5(6)-(3-klor-6-metyl-fenylsulfonyloksy)benzimidazol 2-carbomethoxyamino-5(6)-(3-chloro-6-methyl-phenylsulfonyloxy)benzimidazole
2-karbometoksyamino-5(6)-(4-klor-2-metyl-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-chloro-2-methyl-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(4-klor-3-metyl-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-chloro-3-methyl-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(4-klor-3,5-dimetyl-fenylsulfonyloksy-benzimidazol 2-carbomethoxyamino-5(6)-(4-chloro-3,5-dimethyl-phenylsulfonyloxy-benzimidazole
2-karbometoksyamino-5 (6) - (3-tr i f luormetyl-f enylsulf ony loksy)-benz-;imidaz".Q.l7J::L 2-carbomethoxyamino-5 (6)-(3-trifluoromethyl-phenylsulfonyloxy)-benz-;imidaz".Q.l7J::L
2-karbometoksyamino-5(6)-(4-metoksy-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-methoxy-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(2-metoksy-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(2-methoxy-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(4-propoksy-fenylsulfonyloksy)-benzimidazol 2-Carbomethoxyamino-5(6)-(4-propoxy-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(4-isopropoksy-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-isopropoxy-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(4-butoksy-fenylsulfonyloksy)-benzimidazol 2-Carbomethoxyamino-5(6)-(4-butoxy-phenylsulfonyloxy)-benzimidazole
2-karbometoksyamino-5(6)-(4-isobutoksy-fenylsulfonyloksy)-benzimidazol 2-carbomethoxyamino-5(6)-(4-isobutoxy-phenylsulfonyloxy)-benzimidazole
2-karbetoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-karbopropoksy-5(6)-fenylsulfonyloksy-benzimidazol 2-karbisopropoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-karbobutoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-karbisobutoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2- karbotert.butoksyamino-5(6)-fenylsulfonyloksy-benzimidazol 2-Carbethoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2-Carbopropoxy-5(6)-phenylsulfonyloxy-benzimidazole 2-Carbisopropoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2-Carbobutoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2- carbisobutoxyamino-5(6)-phenylsulfonyloxy-benzimidazole 2- carbotert.butoxyamino-5(6)-phenylsulfonyloxy-benzimidazole
Som utgangsmaterial tjener 2-karbalkoksyamino-5(6)-hydroksy-benzimidazol med formel (2) som fremstilles etter kjente fremgangsmåter/ -sammenliknet DOS 2.164.690. Således omsetter man 3- nitro-4-amino-fenol med benzoylklorid til benzosyre-3-nitro- 4-amino-fen^lester, hydrerer denne forbindelse med Raney-nikkel til 3,4-diaminoderivatet og omsetter dette med S-metyl-tiourin-stoffkarboksylat til 2-karbalkoksyamino-5-benzoyloksy-benzimidazol, hvorav med fortynnet natronlut fås hydroksyforbindelsen med formel (2 ) . 2-carbaloxyamino-5(6)-hydroxy-benzimidazole with formula (2) which is produced according to known methods/ - compared to DOS 2,164,690 serves as starting material. Thus, 3-nitro-4-amino-phenol is converted with benzoyl chloride into benzoic acid 3-nitro-4-amino-phenol ester, this compound is hydrogenated with Raney nickel to the 3,4-diamino derivative and this is reacted with S-methyl- thiourea carboxylate to 2-carbaloxyamino-5-benzoyloxy-benzimidazole, from which with diluted caustic soda the hydroxy compound with formula (2) is obtained.
2-karbalkoksyamino-5(6)-fenylsulfonyloksy-benzi-imidazolet ifølge oppfinnelsen er verdifulle kjemoterapeutica og egner seg til bekjempelse av parasitære sykdommer hos mennes-ker og dyr som fra helminter og leverigler. The 2-carbaloxyamino-5(6)-phenylsulfonyloxy-benzi-imidazole according to the invention are valuable chemotherapeutics and are suitable for combating parasitic diseases in humans and animals such as from helminths and liver leeches.
De er spesielt virksomme for et stort antall helminter, f.eks. Haemonchus, Trichostrongylus, Ostertagia, Strongyloides, Cooperia, Chabertia, Oesophagostomum, Hyostron-gylus, Ankylostoma, Askaris og Heterakis. Spesielt utpreget er virkningen overfor mage-tarm-Strongylider hvorav fremfor alt drøvtyggere angripes. Dyrenes angrep av disse parasitter fører til store økonomiske skader hvor forbindelsene ifølge oppfinnelsen finner spesiell anvendelse i veterinærmidler. They are particularly effective for a large number of helminths, e.g. Haemonchus, Trichostrongylus, Ostertagia, Strongyloides, Cooperia, Chabertia, Oesophagostomum, Hyostron-gylus, Ankylostoma, Askaris and Heterakis. Particularly pronounced is the effect against gastrointestinal Strongylides, of which above all ruminants are attacked. The animals' attack by these parasites leads to great economic damage, where the compounds according to the invention find special use in veterinary medicines.
Virksomme stoffer med formel (1) administreres alt etter tilfelles stilling i doseringer mellom 0,5 og 50 mg pr./kg legemsvekt i 1 til 14 dager. Active substances with formula (1) are administered, depending on the situation of the case, in dosages between 0.5 and 50 mg per kg of body weight for 1 to 14 days.
Til oral applikasjon kommer det i betraktning tabibetter, drageer, kapsler, pulver, granulater eller pastaer som inneholder de virksomme stoffer sammen med vanlig hjelpe-eller bærestoffer som stivelse, cellulosepulver, talkum, magnesiumstearat, sukker, gelatiner, kalciumkarbonat, finfordelt kieselsyre, karboksymetylcellulose eller liknende stoffer. For oral application, tablets, dragees, capsules, powders, granules or pastes containing the active substances together with usual auxiliary or carrier substances such as starch, cellulose powder, talc, magnesium stearate, sugar, gelatins, calcium carbonate, finely divided silicic acid, carboxymethyl cellulose or similar substances.
Til parenteral applikasjon kommer det i betraktning oppløsninger, f.eks. oljeaktige oppløsninger som fremstilles under anvendelse av sesamolje, ricinusolje eller syntetiske triglycerider, eventuelt med en tilsetning av tokoferol som antioksydans og/eller under anvendelse av grenseflateaktive stoffer som sorbitanfettsyreestere. Dertil kommer vandig sus-pensjoner i betraktning som fremstilles under anvendelse av . etoksylerte sorbitan-fettsyreestere eventuelt under tilsetning av fortykningsmidler, som polyetylenglykol eller karboksymetylcellulose. For parenteral application solutions are considered, e.g. oily solutions that are prepared using sesame oil, castor oil or synthetic triglycerides, optionally with the addition of tocopherol as an antioxidant and/or using surfactants such as sorbitan fatty acid esters. In addition, aqueous suspensions are taken into account which are produced using . ethoxylated sorbitan fatty acid esters, optionally with the addition of thickeners, such as polyethylene glycol or carboxymethyl cellulose.
Konsentrasjonen av de virksomme stoffer ifølge oppfinnelsen i de dermed fremstilte preparater ligger fortrinnsvis for bruk som veterinærlegemiddel mellom 2 og 20 vekt-%,for bruk som humanlegemiddel ligger konsentrasjonen av de virksomme stoffer fortrinnsvis mellom 20 og 80 vekt-%. The concentration of the active substances according to the invention in the thus prepared preparations is preferably for use as a veterinary medicine between 2 and 20% by weight, for use as a human medicine the concentration of the active substances is preferably between 20 and 80% by weight.
For å fastslå virkningen av forbindelsene ifølge oppfinnelsen ble det gjennomført kromatografiske undersøkelser på ca. 30 kg tunge sauelam, som eksperimentelt var blitt infisert med larver av Trichostrongylus colubriformis resp. Haemonchus contortus. Forsøksdyrene ble holdt i flislagte bokser som daglig ble renset grundig. Etter forløpet av prepatenstiden (tiden mellom infeksjon og kjønnsmoden etter parasitten med begynnende utskillelse av egg eller larver) ble bestemt til modifiserte McMaster-fremgangsmåten ifølge Wetzel (Tierårztliche Umschau 6, 209 - 210 (1951)) eggtaller pr. gram avføring. Umiddelbart deretter ble det foretatt behandling av sauene (vanligvis 4 til 8 dyr pr. virksomt stoff, minst imidlertid 2). Dyrene ble applisert doseringene av fremgangsmåteproduktene som suspensjon i hver gang 10 ml av en l%ig tylose-suspensjon. Hver gang på In order to determine the effect of the compounds according to the invention, chromatographic examinations of approx. 30 kg sheep lambs, which had been experimentally infected with larvae of Trichostrongylus colubriformis resp. Haemonchus contortus. The experimental animals were kept in tiled boxes which were thoroughly cleaned daily. After the course of the prepatent period (the time between infection and sexual maturity after the parasite with the beginning of excretion of eggs or larvae) was determined according to the modified McMaster method according to Wetzel (Tierårztliche Umschau 6, 209 - 210 (1951)) egg numbers per grams of stool. Immediately thereafter, the sheep were treated (usually 4 to 8 animals per active substance, at least 2, however). The animals were administered the dosages of the process products as a suspension in each time 10 ml of a 1% tylose suspension. Every time on
den 7., 14. og 28. dag etter behandlingen ble det igjen etter ovennevnte fremgangsmåte . f astslåttcejgtall pr. gr. avføring og dens prosentielle nedgang regnes sammenliknet utgangsverdien før behandling. on the 7th, 14th and 28th day after the treatment, it was again according to the above procedure. f estimated numbers per Gr. faeces and its percentage decrease are calculated compared to the starting value before treatment.
Nedenstående tabell gjengir virkningen av noen forbindelser ifølge oppfinnelsen i disse forsøk. The table below reproduces the effect of some compounds according to the invention in these experiments.
Fremgangsmåteproduktene er ikke bare utmerket virksomme oralt applisert, men virker også parenteralt i doseringer ned til 2 mg/kg. Dermed er de langt overlegne sammenlignbare benzimidazolderivater, spesielt alle kjente 5(6)-substituerte 2-benzimidazol-karbaminater. The method products are not only excellently effective orally applied, but also work parenterally in dosages down to 2 mg/kg. Thus, they are far superior to comparable benzimidazole derivatives, especially all known 5(6)-substituted 2-benzimidazole carbamates.
Eksempel 1.Example 1.
Man suspenderer 5,15 g 2-karbometoksyamino-5(6)-hydroksy-benzimidazol i 100 ml aceton og tilsetter 3,5 ml trietylamin. Under kraftig omrøring lar man ved værelsestemperatur en oppløsning av 4,4 g benzensulfonsyreklorid i 20 ml aceton til-dryppe og omrører i 10 timer idet suspensjonens konsistens tydelig endrer seg. Den blir i første rekke tyntflytende og igjen etter hvert tykk. Etter avkjøling frafiltrerer man de faste bestanddeler, vasker i rekkefølge med aceton, vann og metanol og tørker på dampbad. 5.15 g of 2-carbomethoxyamino-5(6)-hydroxy-benzimidazole are suspended in 100 ml of acetone and 3.5 ml of triethylamine are added. With vigorous stirring, a solution of 4.4 g of benzenesulfonic acid chloride in 20 ml of acetone is added dropwise at room temperature and stirred for 10 hours, as the consistency of the suspension clearly changes. It first becomes runny and then gradually thickens. After cooling, the solid components are filtered off, washed in sequence with acetone, water and methanol and dried in a steam bath.
Til rensning omkrystalliseres råproduktet fra iseddik/metanol. Utbyttet av 2-karbometoksyamino-5(6)-fenylsul-fonyl-oksy-benzimidazol utgjør 6,2 g av spaltningspunkt 242°C. Den tynnsjikt-kromatografiske kontroll av reaksjonsblandingen på kieselgel med en blanding av 10 ml kloroform, 10 ml eddiksyreetylester og 1 ml iseddik som løpemiddel viser at flekken av ut-gangsmaterialet er forsvunnet og i dets sted er det trått denne av produksjonsproduktet med høyere R F-verdi. For purification, the crude product is recrystallized from glacial acetic acid/methanol. The yield of 2-carbomethoxyamino-5(6)-phenylsulfonyl-oxy-benzimidazole amounts to 6.2 g of decomposition point 242°C. The thin-layer chromatographic control of the reaction mixture on silica gel with a mixture of 10 ml of chloroform, 10 ml of acetic acid ethyl ester and 1 ml of glacial acetic acid as eluent shows that the stain of the starting material has disappeared and in its place there is this of the production product with a higher R F- value.
Analogt vil man under anvendelse av ekvivalente mengder av de tilsvarende benzensulfonsyreklorider av 5,15 g 2-karbometoksyamino-5(6)-hydroksy-benzimidazol og 2) 5,3 g 4-klor-benzensulfonsyreklorid få Analogously, using equivalent amounts of the corresponding benzenesulfonic acid chlorides, 5.15 g of 2-carbomethoxyamino-5(6)-hydroxy-benzimidazole and 2) 5.3 g of 4-chlorobenzenesulfonic acid chloride will be obtained
6,8 g 2-karbometoksyamino-5(6)-(4-klor-fenylsulfonyloksy)-bensimidazol med smeltepunkt 230°C (under spaltning) 6.8 g of 2-carbomethoxyamino-5(6)-(4-chloro-phenylsulfonyloxy)-benzimidazole with melting point 230°C (under decomposition)
3) 5,3 g 3-klor-benzensulfonsyreklorid få3) Get 5.3 g of 3-chloro-benzenesulfonic acid chloride
6,8 g 2-karbometoksyamino-5(6)-(3-klor-fenylsulfonyloksy)-benzimidazol med smeltepunkt 250°C (under spaltning) 6.8 g of 2-carbomethoxyamino-5(6)-(3-chloro-phenylsulfonyloxy)-benzimidazole with melting point 250°C (under decomposition)
4) 6,15 g 3,4-diklor-benzensulfonsyreklorid få4) Get 6.15 g of 3,4-dichlorobenzenesulfonic acid chloride
7,4 g 2-karbometoksyamino-5(6)-(3,4-diklor-fenylsulfonyloksy)-benzimidazol med smeltepunkt 255°C (under spaltning) 7.4 g of 2-carbomethoxyamino-5(6)-(3,4-dichloro-phenylsulfonyloxy)-benzimidazole with melting point 255°C (under decomposition)
5) 6,15 g 3,5-diklor-benzensulfonsyre-klorid få5) Get 6.15 g of 3,5-dichlorobenzenesulfonic acid chloride
7,3 g 2-karbometoksyamino-5(6)-(3,5-diklor-fenylsulfonyl-oksy) -benzimidazol . med smltepunkt 280°C (under spaltning). 7.3 g of 2-carbomethoxyamino-5(6)-(3,5-dichloro-phenylsulfonyl-oxy)-benzimidazole. with melting point 280°C (under decomposition).
6) 6,4 g 3-brom-benzensulfonsyreklorid få6) Get 6.4 g of 3-bromobenzenesulfonic acid chloride
7,6 g 2-karbometoksyamino-5(6)-(3-brom-fenylsulfonyloksy)-benzimidazol med smeltepunkt 242°C (under spaltning). 7.6 g of 2-carbomethoxyamino-5(6)-(3-bromo-phenylsulfonyloxy)-benzimidazole with melting point 242°C (under decomposition).
7) 4,8 g 4-metyl-benzensulfonsyreklorid få7) Get 4.8 g of 4-methyl-benzenesulfonic acid chloride
6,4 g 2-karbometoksyamino-5(6)-(4-metyl-fenylsulfonyloksy)-benzimidazol med smeltepunkt 237°C (under spaltning). 6.4 g of 2-carbomethoxyamino-5(6)-(4-methyl-phenylsulfonyloxy)-benzimidazole with melting point 237°C (under decomposition).
8) 4,8 g 3-metyl-benzensulfonsyreklorid få8) Get 4.8 g of 3-methyl-benzenesulfonic acid chloride
6,4 g 2-karbometoksyamino-5(6)-(3-metyl-fenylsulfonyloksy)-benzimidazol med smeltepunkt 250°C (under spaltning). 6.4 g of 2-carbomethoxyamino-5(6)-(3-methyl-phenylsulfonyloxy)-benzimidazole with melting point 250°C (under decomposition).
9) 6,1 g 3-trifluormetyl-benzensulfonsyreklorid få9) Get 6.1 g of 3-trifluoromethyl-benzenesulfonic acid chloride
7,4 g 2-karbometoksyamino-5(6)-(3-trifluormetyl-fenylsulfonyl-oksy) -benzimidazol med smeltepunkt 215°C (under spaltning). 7.4 g of 2-carbomethoxyamino-5(6)-(3-trifluoromethyl-phenylsulfonyl-oxy)-benzimidazole with melting point 215°C (under decomposition).
Man vil under anvendelse av 6,1 g 3-trifluormetyl-benzensulf onsyreklorid og One will, using 6.1 g of 3-trifluoromethyl-benzenesulfonic acid chloride and
10) 5,5 g 2-karbetoksyamino-5(6)-hydroksy-benzimidazol få10) 5.5 g of 2-carbethoxyamino-5(6)-hydroxy-benzimidazole get
7,7 g 2-karbetoksyamino-5(6)-(3-trifluormetyl-fenylsulfonyl-oksy) -benzimidazol med smeltepunkt 227°C (under 7.7 g of 2-carbethoxyamino-5(6)-(3-trifluoromethyl-phenylsulfonyl-oxy)-benzimidazole with a melting point of 227°C (below
spaltning).cleavage).
11) 5,9 g 2-karbispropoksyamino-5(6)-hydroksy-benzimidazol få 8,0 g 2-karbispropoksyamino-5(6)-(3-trifluormetyl-fenylsul-fonyloksy) -benzimidazol med smeltepunkt 205°C (under 11) 5.9 g of 2-carbispropoxyamino-5(6)-hydroxy-benzimidazole obtain 8.0 g of 2-carbispropoxyamino-5(6)-(3-trifluoromethyl-phenylsulfonyloxy)-benzimidazole with a melting point of 205°C (below
spaltning)cleavage)
12) 6,2 g 2-karbisbutoksyamino-5(6)-hydroksy-benzimidazol få 8,2 g 2-karbisbutoksyamino-5(6)-(3-trifluormetyl-fenylsul-fonyloksy) -benzimidazol med smeltepunkt 243°C (under 12) 6.2 g of 2-carbisbutoxyamino-5(6)-hydroxy-benzimidazole obtain 8.2 g of 2-carbisbutoxyamino-5(6)-(3-trifluoromethyl-phenylsulfonyloxy)-benzimidazole with a melting point of 243°C (below
spaltning)cleavage)
13) 5,1 g 3-cyano-benzosulfonsyreklorid få13) Get 5.1 g of 3-cyano-benzosulfonic acid chloride
6,7 g 2-karbometoksyamino-5(6)-(3-cyano-fenylsulfonyloksy)-benzimidazol med smeltepunkt 275°C (under spaltning) 6.7 g of 2-carbomethoxyamino-5(6)-(3-cyano-phenylsulfonyloxy)-benzimidazole with melting point 275°C (under decomposition)
For fremstilling av det som utgangsmateriale anvendte 2-karbometoksy-amino-5(6)-hydroksy-benzimidazol blandes 56 g S-metyltiourinstoffsulfat i 90 ml vann med 26 ml klormaursyre-metylester og ved en temperatur under 20°C tildryppes 116 g 25%ig natronlut. Man etteromrører ennå i en halv time og tilsetter deretter en oppløsning som var blitt fremstilt ved hyd-rering av 51,6 g benzosyre-3-nitro-4-amino-fenylester i 250 ml iseddik med Raney-nikkel og frafiltrering av katalysatoren. Man tilsetter 300 ml iseddik, 100 ml vann og 100 ml metanol og koker 2 timer under tilbakeløp. Etter avkjøling isolerer man det utfelte 2-karbometoksyamino-5(6)-benzoyloksy-benzimidazol i et ut-bytte på 41 g med smeltepunkt 280°C (under spaltning). For the preparation of the 2-carbomethoxy-amino-5(6)-hydroxy-benzimidazole used as starting material, 56 g of S-methylthiourea sulphate is mixed in 90 ml of water with 26 ml of chloroformic acid methyl ester and at a temperature below 20°C, 116 g of 25% ig sodium lye. Stirring is continued for half an hour and a solution is then added which had been prepared by hydrogenating 51.6 g of benzoic acid 3-nitro-4-amino-phenyl ester in 250 ml of glacial acetic acid with Raney nickel and filtering off the catalyst. 300 ml of glacial acetic acid, 100 ml of water and 100 ml of methanol are added and boiled for 2 hours under reflux. After cooling, the precipitated 2-carbomethoxyamino-5(6)-benzoyloxy-benzimidazole is isolated in a yield of 41 g with a melting point of 280°C (under decomposition).
Det således dannede 2-karbometoksyamino-5(6)-benzoyl-oksy-benzimidazol omrøres i 5 minutter i en blanding av 400 ml metanol og 400 ml 2n natronlut, oppløsningen filtreres, nøytrali-seres med iseddik og inndampes i vakuum. Residuet blandes med 100 ml vann, det utfelte faste stoff frasuges og utvaskes med metanol og diisopropyleter. Etter omkrystallisering frå iseddik/ metanol 1:1 får man 21 g 2-karbometoksyamino-5(6)-hydroksy-benzimidazol med smeltepunkt 305°C (under spaltning). The 2-carbomethoxyamino-5(6)-benzoyl-oxy-benzimidazole thus formed is stirred for 5 minutes in a mixture of 400 ml of methanol and 400 ml of 2N caustic soda, the solution is filtered, neutralized with glacial acetic acid and evaporated in vacuo. The residue is mixed with 100 ml of water, the precipitated solid is sucked off and washed out with methanol and diisopropyl ether. After recrystallization from glacial acetic acid/methanol 1:1, 21 g of 2-carbomethoxyamino-5(6)-hydroxy-benzimidazole with a melting point of 305°C (under decomposition) is obtained.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19752541752 DE2541752A1 (en) | 1975-09-19 | 1975-09-19 | ANTHELMINTHICALLY ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULFONYLOXY- BENZIMIDAZOLE AND METHOD FOR THEIR PRODUCTION |
Publications (1)
Publication Number | Publication Date |
---|---|
NO763196L true NO763196L (en) | 1977-03-22 |
Family
ID=5956862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO763196A NO763196L (en) | 1975-09-19 | 1976-09-17 | PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES. |
Country Status (12)
Country | Link |
---|---|
AT (1) | AT358575B (en) |
CA (1) | CA1069909A (en) |
CH (1) | CH619938A5 (en) |
DE (1) | DE2541752A1 (en) |
DK (1) | DK141550C (en) |
ES (1) | ES451497A2 (en) |
FI (1) | FI762653A (en) |
GR (1) | GR60799B (en) |
HU (1) | HU172484B (en) |
NO (1) | NO763196L (en) |
PT (1) | PT65607B (en) |
SE (1) | SE7610310L (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4435418A (en) * | 1982-12-13 | 1984-03-06 | Smithkline Beckman Corporation | 5-Phenylethenylbenzimidazoles |
EP1298125A1 (en) * | 2001-09-26 | 2003-04-02 | Aventis Pharma S.A. | Substituted benzimidazole compounds and their use for the treatment of cancer |
FR2868421B1 (en) | 2004-04-01 | 2008-08-01 | Aventis Pharma Sa | NOVEL BENZOTHIAZOLES AND THEIR USE AS MEDICAMENTS |
FR2891273B1 (en) | 2005-09-27 | 2007-11-23 | Aventis Pharma Sa | NOVEL BENZIMIDAZOLE AND BENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE, IN PARTICULAR AS CMET INHIBITORS |
-
1975
- 1975-09-19 DE DE19752541752 patent/DE2541752A1/en active Pending
-
1976
- 1976-09-14 ES ES451497A patent/ES451497A2/en not_active Expired
- 1976-09-16 HU HU76HO00001929A patent/HU172484B/en unknown
- 1976-09-16 FI FI762653A patent/FI762653A/fi not_active Application Discontinuation
- 1976-09-16 SE SE7610310A patent/SE7610310L/en unknown
- 1976-09-17 AT AT690876A patent/AT358575B/en active
- 1976-09-17 CA CA261,425A patent/CA1069909A/en not_active Expired
- 1976-09-17 NO NO763196A patent/NO763196L/en unknown
- 1976-09-17 DK DK419876A patent/DK141550C/en active
- 1976-09-17 PT PT65607A patent/PT65607B/en unknown
- 1976-09-17 CH CH1182076A patent/CH619938A5/en not_active IP Right Cessation
- 1976-09-18 GR GR51724A patent/GR60799B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK141550C (en) | 1980-10-06 |
CA1069909A (en) | 1980-01-15 |
HU172484B (en) | 1978-09-28 |
SE7610310L (en) | 1977-03-20 |
ATA690876A (en) | 1980-02-15 |
FI762653A (en) | 1977-03-20 |
PT65607B (en) | 1978-05-10 |
AT358575B (en) | 1980-09-25 |
DK141550B (en) | 1980-04-21 |
DK419876A (en) | 1977-03-20 |
CH619938A5 (en) | 1980-10-31 |
GR60799B (en) | 1978-08-30 |
DE2541752A1 (en) | 1977-03-24 |
ES451497A2 (en) | 1977-12-01 |
PT65607A (en) | 1976-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU602118A3 (en) | Method of producing benzimidazole derivatives or salts thereof | |
US3954791A (en) | Anthelmintically active 2-carbalkoxy-amino-benzimidazole-5(6)-phenyl ethers | |
NO834773L (en) | SUBSTITUTED PHENYL SULPHONYLOXYBENZIMIDAZOLE CARBAMINATES, PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS A MEDICINE | |
NO763196L (en) | PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVE 2-CARBALCOXYAMINO-5 (6) -PHENYL-SULPHONYLOXY-BENZIMIDAZOLES. | |
NO140592B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVITY 2-CARBALCOXYAMINO-BENZIMIDAZOLYL-5- (6) -SULPHONIC ACID PHENYLES | |
NO140591B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF ANTELMINTIC ACTIVITY 2-CARBALCOXY-AMINO-5 (6) -PHENYL SULPHONYLOXY-BENZIMIDAZOLES | |
NO743436L (en) | ||
US4010272A (en) | Anthelmintically active basically substituted 2-carbalkoxy-amino-benzimidazolyl-5(6)-phenyl ethers and -ketones | |
NO120370B (en) | ||
JPS6216469A (en) | 2-substituted cycloheptoimidazole derivative, antiulcer agent and production thereof | |
US3984561A (en) | Anthelmintically active 2-carbalkoxy-amino-benzimidazole-5(6)-phenyl ethers and method for using the same | |
CA1056828A (en) | Preparation of 2,1,4-benzothiadiazine derivatives | |
KR790001340B1 (en) | Process for preparing 2-carboalkoxy amino-5(6)-phenyl sulfonyloxy benzimidazoles | |
JPS5914027B2 (en) | 2-Carbalkoxyamino-5(6)-phenylsulfonyloxy-benzimidazole compound | |
US4069325A (en) | 3-Carbalkoxyamino-1H-2,1,4-benzothiadiazine derivatives | |
NO751871L (en) | ||
JPS5914026B2 (en) | 2-Carbalkoxyamino-benzimidazolyl-5(6)-sulfonic acid-phenyl ester compound | |
KR790001341B1 (en) | Process for preparing 2-carboalkoxy amino benzimi-dazolyl-5 (6)-sulfonic acid phenyl esters | |
KR910008938B1 (en) | Process for preparing of pyridine derivertes | |
NO763197L (en) | PROCEDURES FOR THE PREPARATION OF ANTELMINTIC ACTIVITY 2-CARBALCOXYAMINO-BENZIMIDAZOLE DERIVATIVES. | |
CS196284B2 (en) | Method of producing phenylesters of 2-alkoxycarbonyl aminobenzimidazol-5/6/-ylsulphonic acid | |
NO763194L (en) | PROCEDURES FOR THE PREPARATION OF ANTELMINTIC ACTIVITY BASIC SUBSTITUTED 2-CARBALCOXYAMINO-BENZIMIDAZOLYL-5 (6) PHENYLETERS AND KETONES. | |
JPS62175481A (en) | Novel sulfoxide derivative and production thereof | |
NO136711B (en) | ||
CS196280B2 (en) | Method of producing 2-alkoxycarbonyl-amino-5/6/-phenylsulphonyl- oxybenzimidazoles |